---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-035195"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2026-09-01T13:26:31+00:00"
generated_at: "2026-09-01T13:27:13.350393+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Crinetics completes $10B acquisition by Vertex at $85/share

## Summary
- Merger completed Sept 1, 2026; Crinetics shareholders receive $85.00 per share cash.
- Aggregate consideration ~$10.0B, funded via Vertex cash and term loan borrowings.
- Crinetics common stock to be delisted from Nasdaq; Form 25 and Form 15 filings to follow.
- All prior directors resigned; Charles Wagner named sole director and President; Prasanna Thombre and Omar White as Treasurer and Secretary.

## SEC filing metadata
- accession: 0001140361-26-035195
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2026-09-01T13:26:31+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000114036126035195/0001140361-26-035195-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000114036126035195/ef20081409_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-035195
- JSON: https://secwatch.observer/filing/0001140361-26-035195.json
- Plain text: https://secwatch.observer/filing/0001140361-26-035195.txt

## Key facts
- Executive change
  Rogério Vivaldi Coelho resigned as Director at Crinetics Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Director
  source text: each of the directors of the Company, R. Scott Struthers, Ph.D., Camille L. Bedrosian, M.D., Caren Deardorf, Matthew K. Fust, Weston Nichols, Ph.D., Stephanie S. Okey, M.S., Rogério Vivaldi Coelho, M.D. and Wendell Wierenga, Ph.D., resigned and ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000114036126035195/0001140361-26-035195-index.htm
- Executive change
  Charles Wagner was appointed as Director at Crinetics Pharmaceuticals, Inc..
  - Action: became
  - Role: Director
  source text: the sole director of Merger Sub immediately prior to the Effective Time became the sole director of the Surviving Corporation. The sole director of Merger Sub immediately prior to the Effective Time was Charles Wagner.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000114036126035195/0001140361-26-035195-index.htm
- Executive change
  Caren Deardorf resigned as Director at Crinetics Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Director
  source text: each of the directors of the Company, R. Scott Struthers, Ph.D., Camille L. Bedrosian, M.D., Caren Deardorf, Matthew K. Fust, Weston Nichols, Ph.D., Stephanie S. Okey, M.S., Rogério Vivaldi Coelho, M.D. and Wendell Wierenga, Ph.D., resigned and ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000114036126035195/0001140361-26-035195-index.htm
- Executive change
  Charles Wagner was appointed as President at Crinetics Pharmaceuticals, Inc..
  - Action: became
  - Role: President
  source text: In connection with the consummation of the Merger, as of immediately after the Effective Time, Charles Wagner, Prasanna Thombre and Omar White became the President, Treasurer and Secretary of the Surviving Corporation, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000114036126035195/0001140361-26-035195-index.htm
- Executive change
  Prasanna Thombre was appointed as Treasurer at Crinetics Pharmaceuticals, Inc..
  - Action: became
  - Role: Treasurer
  source text: In connection with the consummation of the Merger, as of immediately after the Effective Time, Charles Wagner, Prasanna Thombre and Omar White became the President, Treasurer and Secretary of the Surviving Corporation, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000114036126035195/0001140361-26-035195-index.htm
- Executive change
  R. Scott Struthers resigned as Director at Crinetics Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Director
  source text: each of the directors of the Company, R. Scott Struthers, Ph.D., Camille L. Bedrosian, M.D., Caren Deardorf, Matthew K. Fust, Weston Nichols, Ph.D., Stephanie S. Okey, M.S., Rogério Vivaldi Coelho, M.D. and Wendell Wierenga, Ph.D., resigned and ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000114036126035195/0001140361-26-035195-index.htm
- Executive change
  Stephanie S. Okey resigned as Director at Crinetics Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Director
  source text: each of the directors of the Company, R. Scott Struthers, Ph.D., Camille L. Bedrosian, M.D., Caren Deardorf, Matthew K. Fust, Weston Nichols, Ph.D., Stephanie S. Okey, M.S., Rogério Vivaldi Coelho, M.D. and Wendell Wierenga, Ph.D., resigned and ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000114036126035195/0001140361-26-035195-index.htm
- Executive change
  Weston Nichols resigned as Director at Crinetics Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Director
  source text: each of the directors of the Company, R. Scott Struthers, Ph.D., Camille L. Bedrosian, M.D., Caren Deardorf, Matthew K. Fust, Weston Nichols, Ph.D., Stephanie S. Okey, M.S., Rogério Vivaldi Coelho, M.D. and Wendell Wierenga, Ph.D., resigned and ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000114036126035195/0001140361-26-035195-index.htm
- Executive change
  Omar White was appointed as Secretary at Crinetics Pharmaceuticals, Inc..
  - Action: became
  - Role: Secretary
  source text: In connection with the consummation of the Merger, as of immediately after the Effective Time, Charles Wagner, Prasanna Thombre and Omar White became the President, Treasurer and Secretary of the Surviving Corporation, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000114036126035195/0001140361-26-035195-index.htm
- Executive change
  Matthew K. Fust resigned as Director at Crinetics Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Director
  source text: each of the directors of the Company, R. Scott Struthers, Ph.D., Camille L. Bedrosian, M.D., Caren Deardorf, Matthew K. Fust, Weston Nichols, Ph.D., Stephanie S. Okey, M.S., Rogério Vivaldi Coelho, M.D. and Wendell Wierenga, Ph.D., resigned and ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000114036126035195/0001140361-26-035195-index.htm
- Executive change
  Camille L. Bedrosian resigned as Director at Crinetics Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Director
  source text: each of the directors of the Company, R. Scott Struthers, Ph.D., Camille L. Bedrosian, M.D., Caren Deardorf, Matthew K. Fust, Weston Nichols, Ph.D., Stephanie S. Okey, M.S., Rogério Vivaldi Coelho, M.D. and Wendell Wierenga, Ph.D., resigned and ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000114036126035195/0001140361-26-035195-index.htm
- Executive change
  Wendell Wierenga resigned as Director at Crinetics Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Director
  source text: each of the directors of the Company, R. Scott Struthers, Ph.D., Camille L. Bedrosian, M.D., Caren Deardorf, Matthew K. Fust, Weston Nichols, Ph.D., Stephanie S. Okey, M.S., Rogério Vivaldi Coelho, M.D. and Wendell Wierenga, Ph.D., resigned and ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000114036126035195/0001140361-26-035195-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.